TP53 and cancer: This data strongly indicates that the different modulation of Bcl-2/p70S6K pro-tumoral axis may be linked to the different p53 status in cancer cells and that, in the case of PANC-1, the induction of Bcl-2 may partially explain their drug resistance phenotype.